At Ossium, we believe that science is humanity’s best weapon in the fight against disease, and we embrace the challenge of mobilizing the world’s healthcare ecosystem to win that fight. In pursuit of this goal, we empower our employees, maintain the highest standards of excellence, and are a force for good.
CEO, Co-Founder & President
We are mission-driven and results-oriented. We believe that a healthier world is a better one and that our work should drive positive change.
Embracing the truth empowers us to learn from both our successes and our mistakes. We follow the data wherever it leads.
We hold ourselves and each other to the highest bar. We care deeply about the work we do.
Each obstacle we encounter in pursuit of a healthier future only sharpens our resolve. We understand that our vision is worth fighting for.
Recovery Services
These donor tissue recovery experts work with our OPO partners to continuously improve our tissue recovery processes. They are masters of Ossium’s recovery protocols and practices.
Clinical Production
These processing experts make our cell therapy products. They are skilled in tissue processing, cell processing, and cryopreservation.
Clinical
These clinical trial experts advance our clinical program by designing and implementing study protocols, managing research sites, and analyzing clinical trial data. Their work is critical in navigating the complex process of bringing innovative, life-saving treatments to patients in support of Ossium’s mission to improve the health, vitality, and longevity of human beings through bioengineering.
Quality Assurance
These Quality Assurance experts play a crucial role in preventing, detecting, and correcting defects and errors, fostering trust among patients and customers. They develop robust systems that ensure processes and products consistently meet established regulations and standards.
Every day since joining Ossium I've been blown away by the hard work and dedication of each Ossie. There are so many talented individuals that inspire me daily. Our mission is the driving force behind everything we do, knowing that our work will save lives and impact the field of medicine. I’m honored to be part of a company making a difference in the world.
Director, Clinical Production
Director, Clinical Production
From my very first interactions with Ossium in the interview process, I've been genuinely impressed. The 'wow factor' here is driven by people with genuine passion. I feel like I belong to a talented community where we all work together to save lives and make a real impact on human health. I'm incredibly honored to contribute to such a meaningful mission.
Director, Technology
Director, Technology
I really appreciate that Ossium has challenged me in ways that totally throw me out of my comfort zone. It's a wonderful place to learn and grow.
Vice President, Research
Vice President, Research
For the past 20 years, Dr. Johnstone has been actively involved in translating adult stem cell therapies into treatments for a host of diseases affecting the major organs of the body. In 2004, he co-authored one of the first studies demonstrating the potential for treating cardiovascular diseases with novel adult stem cells isolated from fat. At Ossium, Dr. Johnstone leads the Research organization, driving innovation and translating scientific discoveries into practical applications that advance the company mission.
Dr. Johnstone co-founded NeuroFx, an early-stage biotech firm developing a novel therapy for neurological disorders. Dr. Johnstone led the R&D program at NeuroFx for two years, where he was directly responsible for preclinical and chemistry, manufacturing, and controls development activities. He continues to act as an advisor for NeuroFx. Additionally, Dr. Johnstone has formed two other biotech companies: Chemigen, which is developing a small molecule drug for treating Lou Gehrig’s disease, and EmphyMab Biotech (now Allinaire), which is developing biologics to treat serious lung diseases.
Before becoming an entrepreneur, Dr. Johnstone was an early employee at Sangamo Biosciences for 6 years. During this time, he managed the preclinical development program for their lead gene therapy candidate for cardiovascular diseases, which was promoted to clinical testing. Dr. Johnstone received his PhD from the University of Maryland, College Park, and completed a postdoctoral fellowship at the University of California, Los Angeles.
At Ossium, we’re always looking for talented, mission-driven people.
